Clinical Trial

Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated August 19, 2024 (before its estimated September 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
Along with the current clinical trial, the efficacy and safety of a 20 mg rivaroxaban administered within 24 hours of randomization after having first-ever cerebral venous thrombosis compared to apixaban 5mg Bid were assessed through rate of recurrent VTE, mRS, rate of venous recanalization, HIT score, MoCA test, and central and peripheral heamoragic complications.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-28.
Trial Details
NCT Number NCT06531122
Lead Sponsor Kafrelsheikh University
Conditions Cerebral Venous Thrombosis
Enrollment 200 participants
Start Date 2021-08-01
Primary Completion 2024-09-01 (estimated)
Study Completion 2024-09-20 (estimated)
Updated on ClinicalTrials.gov 2024-08-19